Last Updated: May 27, 2024
prevailtherapeutics.com has 2 NS records, 1 A records, 0 AAAA records, 7 MX records, and 2 TXT records. Name servers for prevailtherapeutics.com are ns14.gcd-dns.com, ns13.gcd-dns.com. A records for prevailtherapeutics.com are 192.245.157.40. MX records that process @prevailtherapeutics.com email are mail141prde3.xh1.lilly.com, maillldcprde3.xh1.lilly.com, maillldcprde2.xh1.lilly.com, mail141prde2.xh1.lilly.com, mail141prde1.xh1.lilly.com, maillldcprde1.xh1.lilly.com, prevailtherapeutics-com.mail.protection.outlook.com. We have observed prevailtherapeutics.com to have 3 subdomains. A subdomain count of 3 is considered a small digital footprint. The domain's primary website is hosted on a LiteSpeed web server at 192.245.157.40 in United States. The website's description is: "prevail therapeutics develops disease-modifying aav-based gene therapies for patients with neurodegenerative disorders." As of May 27, 2024, prevailtherapeutics.com does not have any threat intelligence reports of concern.
Search DigitalStakeout Footprint to find another asset.
192.245.157.40
No DNS AAAA records
mail141prde3.xh1.lilly.com
maillldcprde3.xh1.lilly.com
maillldcprde2.xh1.lilly.com
mail141prde2.xh1.lilly.com
mail141prde1.xh1.lilly.com
maillldcprde1.xh1.lilly.com
prevailtherapeutics-com.mail.protection.outlook.com
ns14.gcd-dns.com
ns13.gcd-dns.com
prevailtherapeutics.com. 600 IN TXT "v=spf1 include:spf03.ecicloud.com include:spf.protection.outlook.com ip4:23.253.182.234 ip4:23.253.183.250 ip4:50.23.218.215 ip4:104.130.122.229 ip4:146.20.191.233 ip4:192.237.158.85 ip4:209.61.151.40 ip4:209.61.151.128 ip4:100.12.115.76 ~all"
prevailtherapeutics.com. 600 IN TXT "MS=ms64213076"
prevailtherapeutics.com has 3 subdomains in our inventory.
LiteSpeed
United States
og:locale: en_us
og:type: website
og:title: prevail - aav-based gene therapy
og:description: prevail therapeutics develops disease-modifying aav-based gene therapies for patients with neurodegenerative disorders.
og:url: https://www.prevailtherapeutics.com/
og:site_name: prevail
article:modified_time: 2023-09-28t20:12:58+00:00
{"message_type": "certificate_update", "data": {"leaf_cert": {"not_after": 1688326093, "signature_algorithm": "sha256, rsa", "extensions": {"subjectKeyIdentifier": "23:34:78:34:B6:D6:0D:67:89:15:7C:87:BB:0F:C6:D0:1B:6D:C5:B8", "authorityKeyIdentifier": "keyid:14:2E:B3:17:B7:58:56:CB:AE:50:09:40:E6:1F:AF:9D:8B:14:C2:C6\n", "extendedKeyUsage": "TLS Web server authentication, TLS Web client authentication", "subjectAltName": "DNS:www.prevailtherapeutics.com, DNS:prevailtherapeutics.com", "keyUsage": "Digital Signature, Key Encipherment", "certificatePolicies": "Policy: 1.3.6.1.4.1.44947.1.1.1\n CPS: http://cps.letsencrypt.org", "ctlPoisonByte": true, "authorityInfoAccess": "CA Issuers - URI:http://r3.i.lencr.org/\nOCSP - URI:http://r3.o.lencr.org\n", "basicConstraints": "CA:FALSE"}, "fingerprint": "9D:3B:5E:C7:1C:E1:32:E4:1D:9A:02:2F:FA:4E:83:78:1C:FF:3D:1B", "all_domains": ["prevailtherapeutics.com", "www.prevailtherapeutics.com"], "serial_number": "4A1DC52B4321CD5881192741A90AC7C0A96", "subject": {"C": null, "CN": "prevailtherapeutics.com", "L": null, "O": null, "ST": null, "emailAddress": null, "OU": null, "aggregated": "/CN=prevailtherapeutics.com"}, "not_before": 1680550094, "issuer": {"C": "US", "CN": "R3", "L": null, "O": "Let's Encrypt", "ST": null, "emailAddress": null, "OU": null, "aggregated": "/C=US/CN=R3/O=Let's Encrypt"}}, "cert_link": "https://oak.ct.letsencrypt.org/2023/ct/v1/get-entries?start=491741852&end=491741852", "source": {"url": "https://oak.ct.letsencrypt.org/2023/", "name": "Let's Encrypt 'Oak2023' log"}, "update_type": "PrecertLogEntry", "seen": 1680553705.718551, "cert_index": 491741852}}